Reston, Va. — In an article published in the January 2017 issue of "The Journal of Nuclear Medicine," researchers assert that exposure to medical radiation does not increase a person's risk of getting cancer. The long-held belief that even low doses of radiation, such as those received in diagnostic imaging, increase cancer risk is based on an inaccurate, 70-year-old hypothesis, according to the authors.

"We have shown that the claim made by Hermann Muller during his 1946 Nobel Lecture that all radiation is harmful, regardless of how low the dose and dose rate–known as the linear no-threshold hypothesis (LNTH)–was a non sequitur unrecognized by the radiation science community," states Jeffry A. Siegel, PhD, president and CEO of Nuclear Physics Enterprises, Marlton, New Jersey. "Since then, it has repeatedly been shown that the dose-response relationship may reasonably be considered to be linear but only down to a threshold, below which there is no demonstrable harm and even often benefit. Yet, the LNTH still rules radiation regulatory policy."

Siegel says that policies based on the presumption of harm at every dose level and proposing using lower and lower dosing for CT, x-ray, and nuclear medicine imaging studies–known as the ALARA (as low as reasonably achievable) doctrine–help reinforce existing widespread fear of radiation (radiophobia) in both physicians and patients, due to decades of misinformation. He emphasizes, "This fear is unjustified by any scientific findings and is discredited by most experimental and epidemiological studies, which show that low-dose radiation, instead, stimulates protective responses provided by eons of evolution, resulting in beneficial effects."

Citing numerous studies, the authors assert that the LNTH and ALARA are fatally flawed, as they focus only on molecular damage while ignoring protective, biological responses. Low doses of radiation stimulate protective responses and provide enhanced protections against additional damage over time, including damage from subsequent, higher radiation exposures.

Evidence presented demonstrates a reduced, not increased, cancer risk at radiological imaging doses. The Life Span Study (LSS) atomic-bomb survivor data show the LNTH-predicted, low-dose carcinogenicity is invalid below approximately 200 mGy. The effective dose of a typical computed tomography (CT) scan is about 10 mSv; a PET/CT brain scan, 5-7 mSv; and a routine whole-body F-18 FDG PET/CT scan, 12-15 mSv. Thus, medical imaging's much lower doses for children or adults should not be feared or avoided for radiophobic reasons. The authors reason that the actual risk of misdiagnoses from inadequate dose, or from phobia-driven avoidance of needed imaging studies, should be the main concern.

Siegel advocates for the safety and life-saving benefits of medical imaging, saying, "The task before us is to undo the public's groundless fears of low-dose radiation exposure. The medical profession must be properly re-educated, beginning with diagnostic radiologists and nuclear medicine physicians, and only then can the public be given valid information that they can trust. Furthermore, defeating the LNTH and its offspring ALARA may lead to new ways of diagnosing and treating illness, and, even more importantly, preventing it."

Please visit the SNMMI Media Center to view the PDF of the study, including images, and more information about molecular imaging and personalized medicine. To schedule an interview with the researchers, please contact Laurie Callahan at (703) 652-6773 or [email protected] Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.

About the Society of Nuclear Medicine and Molecular Imaging

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.

SNMMI's more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.snmmi.org.